17 vaccines are now in Phase 3, the final stage of human trials.
One of the advantages of having so many different ones is that some will work better than others and we can use that to narrow down the best approach to take for improved second generation vaccines.
Another is that it's also impossible for any one vaccine maker to cover the needs of the whole world, plus having many prevents any one company having a monopoly on such an important asset.